| Rhonda Ware-redden, LLMFT | |
|
42815 Garfield Rd Ste 201, Clinton Twp, MI 48038-1143 | |
| (586) 333-5328 | |
| (586) 948-9304 |
| Full Name | Rhonda Ware-redden |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 42815 Garfield Rd Ste 201, Clinton Twp, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992453286 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 4151001050 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rhonda Ware-redden, LLMFT 23689 Whitley Dr, Clinton Township, MI 48035-4638 Ph: (313) 310-9345 | Rhonda Ware-redden, LLMFT 42815 Garfield Rd Ste 201, Clinton Twp, MI 48038-1143 Ph: (586) 333-5328 |
News Archive
The International Osteoporosis Foundation is calling on doctors in the Asia-Pacific region to prepare for an immense rise in the number of elderly people suffering broken bones as a result of osteoporosis.
Researchers have found that a rare but hard-to-treat form of breast cancer is driven by a newly discovered gene. The gene ZNF703 is the first oncogene to be discovered in five years, and it could lead to more effective treatments down the road, Cancer Research UK said.
Malignant hyperthermia (MH) is a life-threatening genetic muscle disorder, most commonly triggered in those at risk by certain types of drugs used during anesthesia. Heat stroke, on the other hand, most commonly occurs in individuals in response to physical exertion in hot/humid environments. While their common triggers may differ, the signs associated with MH and heat stroke are remarkably similar - uncontrolled muscle contractions, dangerous increases in body temperature, and muscle breakdown leading to the release of toxins in the blood which may cause cardiac arrhythmias and death. Immediate treatment for these conditions is crucial.
EU regulators met with the marketing authorisation holder of Vioxx (rofecoxib), Merck Sharp & Dohme, on 4-5 October 2004 at the informal meeting of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) held in Scheveningen, The Netherlands.
The Lancet Oncology published this week findings from a study, which showed that the new oral therapy IMNOVID®▼ (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).1
› Verified 3 days ago